Maximus Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals passing. Shareholders could submit questions, and final voting results will be filed with the SEC.
-
Solid Q1 results led to raised earnings and narrowed revenue guidance for FY26, with strong performance in U.S. Federal Services and ongoing tech-driven transformation. Award activity was light due to the government shutdown, but the sales pipeline and AI initiatives position the business for future growth.
Fiscal Year 2025
-
Fiscal 2025 saw higher-than-expected revenue and profitability, with strong growth in U.S. federal services and significant investments in AI and technology. Fiscal 2026 guidance anticipates margin expansion and robust cash flow, despite a slight revenue dip, as the company positions for major growth opportunities in 2027 and beyond.
-
Record Q3 results with 24% EPS growth and 15% adjusted EBITDA increase, leading to raised full-year guidance. Strong federal segment performance, new legislative opportunities, and a major DoD contract support a positive outlook, with cash flow and leverage expected to normalize.
-
Q2 revenue grew 1% (3% organic) to $1.36B, with adjusted EBITDA margin at 13.7% and EPS at $2.01. Guidance for FY25 was raised, reflecting strong federal segment growth and operational efficiencies, while the pipeline remains robust despite procurement delays and macro uncertainty.
-
Strong Q1 results with 5.7% revenue growth and raised full-year guidance, driven by robust U.S. Federal Services performance, successful contract wins, and strategic divestitures. Accelerated share repurchases and a healthy pipeline support continued optimism.
Fiscal Year 2024
-
FY 2024 saw 8.8% organic revenue growth, record adjusted EPS, and strong free cash flow, with robust performance across segments. FY 2025 guidance anticipates steady margins and modest organic growth amid procurement timing risks and a strong contract pipeline.
-
Q3 saw 10.6% revenue growth and margin expansion, prompting a third consecutive guidance raise. Non-recurring Medicaid and federal program volumes drove overperformance, with FY25 expected to normalize but maintain strong margins and cash flow.